Sensitivity of the Elecsys Nucleocapsid Assay for the Detection of Preceding SARS-CoV-2 Infections. (26th July 2022)

• Record Type: Journal Article
• Authors: Grunau, Brian; Tom, Janessa; Asamoah-Boaheng, Michael; O'Brien, Sheila F; Drews, Steven J; Sediqi, Sadaf; Lavoie, Pascal M; Barakauskas, Vilte; Goldfarb, David M
• Is Part Of: Open forum infectious diseases. Volume 9:Number 8(2022)
• Publication Date: 2022-07-26
• Subjects: SARS-CoV-2 -- COVID-19 -- vaccine -- antibodies -- nucleocapsid; Communicable diseases -- Periodicals; Medical microbiology -- Periodicals; Infection -- Periodicals; 616.9
• DOI: 10.1093/ofid/ofac349
• Languages: English
• ISSNs: 2328-8957

Abstract

Abstract: Nucleocapsid serological assay sensitivity to identify severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections among vaccinees and for Omicron cases is unclear. In this prospective study, the Elecsys nucleocapsid assay was 89% sensitive in identifying SARS-CoV-2 infections 14–607 days pre–blood collection. Sensitivity was similar when comparing by vaccination status, and in Omicron (vs pre-Omicron) cases.